Issels Non-Toxic Cancer Immunotherapy and Non-Toxic Cancer Treatment Vaccines
Issels Non-Toxic Cancer Immunotherapy Achieves Long-Term Remission of Advanced and Therapy-Resistant Cancers
The Issels® Immunotherapy for Cancer program incorporates cutting-edge specific autologous (prepared from the patient’s own immune cells) non-toxic vaccine and cell therapy protocols, which have no adverse side-effects.
Issels® Cancer Immunotherapy integrates the vaccine and cell therapies into an individualized treatment program that specifically targets the tumor microenvironment to optimize the results.
Recent research findings reveal the crucial role of the tumor microenvironment in the progression or regression of cancer and confirm our clinical experience of over 60 years with the Issels® Integrative Immunotherapy for Cancer program and its extensive track record of complete long-term cancer remissions.
Non-Toxic Cancer Vaccines – Personalized Targeting of Your Cancer
• Extracorporeal Photopheresis with the Autologous Dendritic Cell Cancer Vaccine
Extracorporeal Photopheresis is a leukapheresis-based immune-modulatory therapy. It is FDA-approved for cutaneous T-cell lymphoma based on research by Richard L. Edelson, Carole L. Berger et al, at Yale University.
During Extracorporeal Photopheresis the blood passes through an ultraviolet light chamber, which has an enormous immune boosting effect. In the cell separator white blood cells, the cells of the immune system such as monocytes and lymphocytes, are separated from the blood, which is then returned to the body in a closed circuit.
These separated monocytes are cultured outside the body into active dendritic cells. When these potent dendritic cells are re-injected into the body they have the potential to invoke an anti-tumor immune system response. Read more »
• Non-Toxic Autologous Dendritic Cell Cancer Vaccine
The Dendritic cell vaccine, approved by the US FDA since 2010, is a potent form of immunotherapy that harnesses the body’s own immune system to fight its cancer. Dendritic cells are key regulators of the immune responses and orchestrate innate and adaptive immunities.
As the most potent antigen presenting immune cells, dendritic cells are responsible for identifying pathogens (malignant cells, viruses, fungi, bacteria) and presenting their identifying markers, antigens, to specific T-lymphocytes that then multiply and attack the disease.
These dendritic cells are also capable of identifying normal dying cells and presenting their antigens to different T-cells that tell the immune system not to attack its own tissues. Read more »
• Non-Toxic Prostate Cancer Vaccine
The Prostate Cancer Vaccine is designed to stimulate a patient’s immune system to target prostate cancer cells. The preparation of the vaccine involves culturing the patient’s peripheral monocytes in vitro in the presence of a recombinant growth factor, special cytokines and their own prostate-specific antigen, which is fractionated into peptides in order to achieve a more specific immune response. Read more »
• Coley’s Mixed Bacterial Vaccine
Research findings suggest that the Coley’s Mixed Bacterial vaccine activates the innate immune system, opens blockades in the body’s connective tissues, enhances the formation of the body’s own interferons, interleukins, colony stimulating factors, tumor necrosis factor, and other potent disease fighters. Read more »
• Issels’ Autologous Vaccine
Issels autologous vaccine is cultured from the patient’s own blood that represents his/her own unique internal bodily environment. The preparation follows procedures that favor the development of antigenic peptides and other immunogenic compounds aiming to enhance the body’s own cancer fighting mechanisms. Read more »
Immunotherapy for cancer is based on the principle that the host’s immune system is capable of generating immune responses against tumor specific antigens. Natural Killer Cells (NKC), in particular, have been shown to eliminate solid tumors and metastatic cells in the circulation through their cytotoxicity and cytokine production.
In a recent study, a retrospective analysis of Natural Killer Cells (NKC) counts included 129 cancer patients who underwent the Issels Treatment® program at the Issels Medical Center in Santa Barbara, California. NKC response to the Issels Treatment® protocol revealed an average 48% increase in absolute NKC levels per patient in approximately 3 weeks.